Race reporting and disparities in clinical trials on Alzheimer’s disease: A systematic review
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
INTRODUCTION Race is an important health determinant and should adequately be considered in research and drug development protocols targeting Alzheimer's disease (AD). METHODS A systematic review of available randomized controlled trials (RCTs) on the currently marketed treatments for AD was conducted with the aim of 1) documenting the reporting of race, and 2) exploring the impact of race on the efficacy and safety/tolerability of the considered medications. RESULTS Overall, 59.2% of the 49 retained RCTs reported information concerning the race of participants. Only a striking minority of enrolled patients was constituted of blacks and Hispanics. None on the retained studies reported results on the efficacy and safety/tolerability of the tested treatment separately for racial groups nor performed sensitivity analyses accounting for the race of participants. DISCUSSION Race has insufficiently been reported in previous interventional studies on AD. Its potential association with the effectiveness and safety/tolerability of the tested medications has completely been neglected.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities
Murthy, V. H., Krumholz, H. M., & Gross, C. P. (2004) · JAMA · doi:10.1001/jama.291.22.2720 · Cited by 2,078
Sex differences in Alzheimer disease — the gateway to precision medicine
for the Women’s Brain Project and the Alzheimer Precision Medicine Initiative, Ferretti, M. T., Iulita, M. F., Cavedo, E., Chiesa, P. A., Schumacher Dimech, A., Santuccione Chadha, A., Baracchi, F., Girouard, H., Misoch, S., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0032-9 · Cited by 1,009
Inequalities in dementia incidence between six racial and ethnic groups over 14 years
Mayeda, E. R., Glymour, M. M., Quesenberry, C. P., & Whitmer, R. A. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.12.007 · Cited by 883
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782
Alzheimer's disease drug development pipeline: 2018
Cummings, J., Lee, G., Ritter, A., & Zhong, K. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.009 · Cited by 697
Use of race and ethnicity in biomedical publication
Kaplan, J. B. (2003) · JAMA · doi:10.1001/jama.289.20.2709 · Cited by 609
Systematic review of dementia prevalence and incidence in United States race/ethnic populations
Mehta, K. M., & Yeo, G. W. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.2360 · Cited by 439
Yaffe, K., Falvey, C., Harris, T. B., Newman, A., Satterfield, S., Koster, A., Ayonayon, H., Simonsick, E., & Study, F. T. H. A. (2013) · BMJ · doi:10.1136/bmj.f7051 · Cited by 363
Cited by
Impact of dementia: Health disparities, population trends, care interventions, and economic costs
Aranda, M. P., Kremer, I. N., Hinton, L., Zissimopoulos, J., Whitmer, R. A., Hummel, C. H., Trejo, L., & Fabius, C. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17345 · Cited by 390
Diversity in Alzheimer's disease drug trials: the importance of eligibility criteria
Franzen, S., Smith, J. E., van den Berg, E., Rivera Mindt, M., van Bruchem‐Visser, R. L., Abner, E. L., Schneider, L. S., Prins, N. D., Babulal, G. M., & Papma, J. M. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12433 · Cited by 146
“The CDR has considerable merits, but researchers and clinicians need to be aware of possible cultural differences that may bias the results, such as (1) downplaying of cognitive symptoms out of respect for older family members, (2) different perceptions of what “normal” daily functioning may entail, (3) the need for a…”
Udeh-Momoh, C., & Watermeyer, T. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101459 · Cited by 67
Ashford, M. T., Raman, R., Miller, G., Donohue, M. C., Okonkwo, O. C., Mindt, M. R., Nosheny, R. L., Coker, G. A., Petersen, R. C., Aisen, P. S., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12640 · Cited by 51
Metadata
- Authors
- Canevelli, M., Bruno, G., Grande, G., Quarata, F., Raganato, R., Remiddi, F., Valletta, M., Zaccaria, V., Vanacore, N., & Cesari, M.
- Venue
- Neuroscience & Biobehavioral Reviews
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 101
- Pages
- 122-128
- ISSN
- 0149-7634 (ISSN-L)
- OpenAlex
- W2928592311
- Cited by
- 91
- References
- 13
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Race reporting and disparities in clinical trials on Alzheimer’s disease: A systematic review. https://app.cochat.ai/papers/10.1016/j.neubiorev.2019.03.020
- The paper
- Canevelli, M., Bruno, G., Grande, G., Quarata, F., Raganato, R., Remiddi, F., Valletta, M., Zaccaria, V., Vanacore, N., & Cesari, M. (2019). Race reporting and disparities in clinical trials on Alzheimer’s disease: A systematic review. Neuroscience & Biobehavioral Reviews. https://doi.org/10.1016/j.neubiorev.2019.03.020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.